ID   MES-SA/Dx1
AC   CVCL_4T93
SY   Mes-SA Dx1; MESSA-DX1; Dx1
DR   cancercelllines; CVCL_4T93
DR   Wikidata; Q54905249
RX   PubMed=4028002;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Uterus; UBERON=UBERON_0000995.
DI   NCIt; C6339; Uterine corpus sarcoma
DI   ORDO; Orphanet_213620; Sarcoma of the corpus uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1404 ! MES-SA
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 05-10-23; Version: 9
//
RX   PubMed=4028002;
RA   Harker W.G., Sikic B.I.;
RT   "Multidrug (pleiotropic) resistance in doxorubicin-selected variants
RT   of the human sarcoma cell line MES-SA.";
RL   Cancer Res. 45:4091-4096(1985).
//